Analysis of circulating cell-free DNA identifies multi-clonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors

Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination (HRR) such as BRCA2. HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib. In ovarian or breast cancers, olaparib resistance ha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Discov
Hauptverfasser: Quigley, David, Alumkal, Joshi J., Wyatt, Alexander W., Kothari, Vishal, Foye, Adam, Lloyd, Paul, Aggarwal, Rahul, Kim, Won, Lu, Eric, Schwartzman, Jacob, Beja, Kevin, Annala, Matti, Das, Rajdeep, Diolaiti, Morgan, Pritchard, Colin, Thomas, George, Tomlins, Scott, Knudsen, Karen, Lord, Christopher J, Ryan, Charles, Youngren, Jack, Beer, Tomasz M., Ashworth, Alan, Small, Eric J., Feng, Felix Y.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581695/
https://ncbi.nlm.nih.gov/pubmed/28450426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0146
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge